相关临床试验
12
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
6
50.0%
已完成
3
25.0%
招募中
2
16.7%
暂停
1
8.3%
暂无批准数据
- Researchers from Trinity College Dublin and University College Dublin demonstrated for the first time that dietary yeast beta-glucan reprograms bone marrow stem cells to enhance anti-tumor immune responses. - The supplement restored innate immunity in obese mice and reversed long-term immune memory defects that persist even after weight loss, a major unmet clinical challenge. - Yeast beta-glucan is already widely used as a food supplement with an excellent safety record, making it a realistic candidate for clinical translation. - The study, published in Cell Reports, showed efficacy across colorectal, skin, and breast cancer models in mice fed either standard or high-fat diets.
- Scientists at the University of Cambridge have developed an innovative LED-powered method for modifying complex drug molecules that eliminates the need for toxic chemicals and harsh conditions. - The breakthrough "anti-Friedel–Crafts" reaction allows precise molecular modifications at late stages of drug development, potentially accelerating pharmaceutical research by months. - The discovery emerged from a failed control experiment and demonstrates how serendipitous findings can lead to transformative advances in medicinal chemistry. - The method shows strong potential for industrial application through collaboration with AstraZeneca and adaptation to continuous-flow systems used in pharmaceutical manufacturing.
- Researchers at Trinity College Dublin have developed a needle-free nasal vaccine using antibiotic-inactivated Bordetella pertussis (AIBP) that prevents both whooping cough infection and bacterial transmission. - The vaccine outperformed current injected vaccines in preclinical mouse studies by activating T-cells and providing mucosal immunity directly at respiratory infection sites. - This breakthrough addresses a critical gap in whooping cough prevention, as current vaccines protect against severe disease but fail to prevent bacterial colonization and community spread. - The technology could serve as a platform for developing vaccines against other respiratory pathogens including tuberculosis and pneumonia-causing bacteria.
- A Taiwan study published in the Journal of Wound Care shows MolecuLight's real-time fluorescence imaging significantly improves infection control in deep sternal wound infections, with 26-fold higher likelihood of normalized white blood cell counts within 7 days. - The technology reduced antibiotic use duration from 29.5 to 22 days and cut antibiotic costs by nearly two-thirds, while patients experienced 70% shorter ICU stays and 20% faster complete wound healing. - MolecuLight imaging was associated with 82% lower risk of in-hospital wound reinfection and 86% lower risk of recurrent osteomyelitis compared to standard hyperbaric oxygen therapy. - A systematic review by Trinity College Dublin researchers analyzing 17 studies confirms MolecuLight's clinical utility, with the technology leading clinicians to change treatment plans 68.9% of the time.
- ANGLE's Parsortix system has enabled multiple breakthrough studies published in high-impact journals, revealing novel insights into circulating tumor cell biology and cancer metastasis mechanisms. - Research published in Nature Genetics demonstrates that CTC clusters exhibit significant genetic diversity and are up to 100 times more metastatic than individual CTCs, making them critical targets for preventing cancer spread. - Additional studies using the Parsortix platform have uncovered substantial tumor cell release during prostate and ovarian cancer surgeries, opening new avenues for understanding surgical risks and developing protective strategies. - The mechanical conditioning research in breast cancer patients revealed progressive increases in metastatic potential through the cancer cascade, potentially guiding treatment selection with anti-fibrotic drugs.
